Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV-Reference-Cited by-同舟云学术

Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV

Published:2020-07-21 Issue:13 Volume:34 Page:1899-1906
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Trunfio Mattia,Rugge Walter,Mighetto Lorenzo,Vai Daniela,Atzori Cristiana,Nigra Marco,Domini Simone,Borgogno Enrica,Guastamacchia Giulia,Bonora Stefano,Di Perri Giovanni,Calcagno Andrea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference41 articles.

1. Dual antiretroviral therapy for HIV infection;Soriano;Expert Opin Drug Saf,2017

2. Central nervous system HIV infection in ‘less-drug regimen’ antiretroviral therapy simplification strategies;Ferretti;Semin Neurol,2014

3. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence;Orkin;HIV Med,2018

4. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?;Moreno;HIV Med,2019

5. Mechanisms of HIV persistence in HIV reservoirs;Mzingwane;Rev Med Virol,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen;Journal of Neuroimmune Pharmacology;2023-10-31

2. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study;JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-07-01

3. The presence of resistance‐associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV‐1 escape: A multicentric retrospective analysis;Journal of Medical Virology;2023-04

4. Two-drug regimens for HIV treatment;The Lancet HIV;2022-12

5. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12